CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy is approved for B cell malignancies and multiple myeloma.
• Efficacy of CAR T-cells against solid tumors remains limited, hindering clinical understanding due to scarce data.
• Preclinical models are currently relied upon due to insufficient clinical imaging and biopsy data.

Purpose of the Study:

• To re-evaluate current data on CAR T-cell therapy for solid tumors.
• To identify promising strategies for enhancing CAR T-cell efficacy in solid tumors.
• To draw lessons from successful solid tumor CAR T-cell trials and tumor-infiltrating lymphocyte (TIL) therapy.

Main Methods:

• Review and analysis of existing clinical trial data for CAR T-cells in solid tumors.
• Examination of clinical experience with tumor-infiltrating lymphocytes (TILs).
• Identification of novel therapeutic strategies based on current research.

Main Results:

• Several promising approaches for solid tumor CAR T-cell therapy were identified.
• Strategies include using pluripotent stem cells, co-targeting immune evasion, employing multiple co-stimulatory domains, and CAR ligand-targeting vaccines.
• An alternative strategy involves administering multiple doses of short-lived CAR T-cells to prevent exhaustion.

Conclusions:

• CAR T-cell therapy holds potential for solid tumors, but significant challenges remain.
• Innovative strategies are crucial for overcoming current limitations and improving patient outcomes.
• Further research and clinical trials are needed to validate these promising approaches.